Casein Kinase

Casein kinase 1δ-IN-19 is a selective inhibitor of casein kinase 1δ, a key enzyme involved in various signaling pathways. This compound exhibits potent inhibitory activity, making it valuable for investigating the molecular mechanisms underlying neurodegenerative diseases, including Alzheimer's disease. It serves as an important tool for researchers exploring therapeutic strategies targeting CK1δ in these conditions.

WAY-606344 is an inhibitor of Casein kinase 1δ, a key regulatory enzyme involved in various cellular processes. This compound is primarily investigated for its potential in Alzheimer's disease research, where modulation of kinase activity may impact neurodegenerative pathways. Its application in studying CK1δ signaling can contribute to understanding disease mechanisms and the development of therapeutic strategies.

Casein kinase 1δ-IN-5 is a selective inhibitor of casein kinase 1δ, exhibiting an IC50 of 47 nM. This compound demonstrates neuroprotective and anti-inflammatory effects in vitro, making it a valuable tool for studying neurodegenerative diseases. Its ability to modulate CK-1δ activity provides insights into various cellular processes and potential therapeutic applications in neurological research.

Casein kinase 1δ-IN-17 is a selective inhibitor of casein kinase 1δ (CK1δ). This compound has shown potential in modulating CK1δ activity, which plays a significant role in various cellular processes. Its primary application is in the research of neurodegenerative disorders, where targeting CK1δ may provide insights into disease mechanisms and therapeutic strategies.

Casein kinase 1δ-IN-22 is a potent inhibitor of casein kinase 1δ, an enzyme implicated in various cellular processes. This compound is valuable for investigating the role of casein kinase 1δ in neurodegenerative diseases, including Alzheimer's disease. Its inhibitory activity allows for the exploration of cellular signaling pathways and potential therapeutic strategies targeting CK1δ-related disorders.

Casein kinase 1δ-IN-18 is a selective inhibitor of casein kinase 1δ (CK1δ). This compound is valuable in research focused on neurodegenerative disorders, where CK1δ plays a critical role in various signaling pathways. By inhibiting CK1δ, Casein kinase 1δ-IN-18 can help elucidate the mechanisms underlying these diseases and aid in the development of potential therapeutic strategies.

CK1δ-IN-9 is a potent inhibitor of casein kinase 1 delta (CK1δ) with an IC50 value of 1.4 nM. This compound also demonstrates inhibitory effects on p38α and p38β with IC50 values of 0.25 μM and 0.78 μM, respectively. CK1δ-IN-9 has favorable pharmacokinetic properties, including 70% oral bioavailability and moderate clearance, making it suitable for research applications in kinase signaling pathways and therapeutic potential in related diseases.

CX-5279 is a selective inhibitor of casein kinase 2 (CK2), exhibiting IC50 values of 2.73 nM for nCK2 and 0.91 nM for CK2α. This compound demonstrates variable sensitivity to specific mutations, with altered IC50 values of 13.8 nM, 12.5 nM, and 23.35 nM for mutations at Val66 and Ile174. Although CX-5279 shows limited inhibitory activity against PIM1 (IC50 = 8.52 μM), it has been reported to possess anti-proliferative effects in various cancer cell lines. This reagent is applicable in research focused on pancreatic cancer and leukemia.

CK1δ-IN-6 is a selective inhibitor of Casein Kinase 1δ (CK1δ), targeting a key enzyme involved in cellular signaling pathways. Its inhibition has been linked to potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. Research utilizing CK1δ-IN-6 can elucidate the role of CK1δ in cellular processes and its contribution to disease progression, making it a valuable tool for uncovering new insights into Alzheimer's pathology.

Tyrphostin AG1112 is a potent inhibitor of casein kinase II (CK II). It demonstrates notable inhibition of the p210bcr-abl tyrosine kinase, with IC50 values of 2 μM for p210bcr-abl, 15 μM for epidermal growth factor receptor (EGFR), and 20 μM for platelet-derived growth factor receptor (PDGFR) in relevant cellular models. This compound is valuable for research investigating cancer signaling pathways and therapeutic interventions targeting kinase activity.

Casein kinase 1δ-IN-31 is a selective inhibitor of casein kinase 1 (CK1), demonstrating potent inhibitory activity against CK1α, CK1δ, and p38α with IC50 values of 196 nM, 17 nM, and 18 nM, respectively. Additionally, this compound inhibits Double Homeobox 4 (DUX4) with an IC50 of 1200 nM. Casein kinase 1δ-IN-31 is primarily utilized in research applications to explore CK1 signaling pathways and their roles in various cellular processes and diseases.

4,5,6,7-Tetrabromo-1H-benzimidazole is a selective inhibitor of casein kinase 2 (CK2), functioning through an ATP-competitive mechanism. This compound has been shown to effectively inhibit CK2 activity, making it a valuable tool for investigating the role of CK2 in various cellular processes. Its primary applications include studies on cell proliferation, apoptosis, and signal transduction pathways. Researchers may utilize this reagent to explore CK2's involvement in cancer and other disease states.

CK1δ-IN-7 is a selective inhibitor of casein kinase 1δ (CK1δ), a crucial mediator in various cellular signaling pathways. This compound exhibits potent inhibition of CK1δ activity, making it a valuable tool for investigating the role of CK1δ in cellular processes such as circadian rhythms, cellular proliferation, and apoptosis. Researchers can utilize CK1δ-IN-7 in studies related to cancer, neurodegenerative diseases, and other pathophysiological conditions linked to CK1δ signaling dysregulation.

CK1δ-IN-8 is a selective inhibitor of casein kinase 1 delta (CK1δ), a crucial regulator in various cellular signaling pathways. This compound demonstrates significant potential in Alzheimer's disease research by modulating phosphorylation processes linked to protein aggregation and neurodegeneration. Its application may aid in elucidating the molecular mechanisms underlying Alzheimer's and developing therapeutic strategies.

Casein kinase 1δ-IN-30 is a selective inhibitor of Casein kinase 1δ (CK1δ). This compound demonstrates significant biological activity in modulating CK1δ activity, making it a valuable tool for investigating neurodegenerative diseases and related pathways. Its application in research can enhance understanding of CK1δ's role in cellular processes and potential therapeutic targets in neurodegeneration.

CK1δ-IN-5 is a selective inhibitor of Casein kinase 1δ (CK1δ), a key enzyme involved in various cellular processes. This compound plays a significant role in the study of neurodegenerative diseases by modulating upstream signaling pathways that may contribute to neuronal dysfunction. Researchers can utilize CK1δ-IN-5 to explore potential therapeutic targets and elucidate the molecular mechanisms underlying these diseases.

CK1-IN-5 is a selective inhibitor of Casein Kinase 1 (CK1). It has been shown to extend the circadian period by inhibiting the activity of AtCKL3 and AtCKL4. This compound is of significant interest in circadian rhythm research and offers potential applications in studies of sleep disorders and metabolic regulation.